NYRADA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.094 AUD | 0.00% |
|
-4.08% | +327.27% |
| 30/04 | Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury | MT |
| 18/04 | Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024 |
| Sales 2022 | 1.09 1.69 91.26 | Sales 2023 | 1.43 2.21 119.31 | Capitalization | 4.37M 6.75M 364M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -4.64M -250M | Net income 2023 | -7M -10.82M -584M | EV / Sales 2022 | 93,67,032 x |
| Net cash position 2022 | 10.82M 16.71M 902M | Net cash position 2023 | 3.71M 5.73M 309M | EV / Sales 2023 | 4,61,207 x |
| P/E ratio 2022 |
-4.5
x | P/E ratio 2023 |
-0.56
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 30.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nyrada Inc.
More press releases
| 1 week | -4.08% | ||
| Current month | -5.05% | ||
| 1 month | +3.30% | ||
| 3 months | +327.27% | ||
| 6 months | +327.27% | ||
| Current year | +327.27% |
1 week
0.09
0.10
1 month
0.090.15
Current year
0.020.17
1 year
0.020.17
3 years
0.020.37
5 years
0.020.46
10 years
0.020.46
| Managers | Title | Age | Since |
|---|---|---|---|
James Bonnar
CEO | Chief Executive Officer | - | 01/18/01 |
| Founder | - | 29/17/29 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 29/17/29 | |
Ruediger Weseloh
BRD | Director/Board Member | - | 01/19/01 |
Marcus Frampton
BRD | Director/Board Member | 44 | 01/19/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/24/01 | 0.094 | 0.00% | 213 465 |
| 30/24/30 | 0.094 | -1.05% | 618,536 |
| 29/24/29 | 0.095 | +1.06% | 558,347 |
| 26/24/26 | 0.094 | -2.08% | 1,351,825 |
| 24/24/24 | 0.096 | -2.04% | 321,445 |
Delayed Quote Australian S.E., May 01, 2024 at 07:44 am IST
More quotes
Nyrada Inc. is a preclinical stage, drug development company specializing in small molecule drugs to treat cardiovascular and neurological diseases. The Companyâs two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. It is also developing new therapies.
Sector
Pharmaceuticals
Calendar
16/05/2024
- Extraordinary Shareholders Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +327.27% | 11.18M | |
| +34.00% | 664B | |
| +29.29% | 567B | |
| -7.75% | 354B | |
| +18.53% | 330B | |
| +4.95% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.89% | 148B |
- Stock Market
- Equities
- NYR Stock
